Toxicity of tapentadol: a systematic review

被引:20
作者
Channell, Jessie S. [1 ]
Schug, Stephan [1 ]
机构
[1] Univ Western Australia, Sch Med, Perth, WA, Australia
关键词
adverse event; adverse-effect; mortality; Nucynta; overdose; Palexia; poison; tapentadol; toxicity; safety;
D O I
10.2217/pmt-2018-0027
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Tapentadol is a novel atypical opioid. Anecdotal evidence suggests that tapentadol has a lower toxicity than conventional opioids. Objectives: To evaluate all single-drug mortality due to tapentadol and assess serious adverse events caused by tapentadol. Methods: The Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) reporting guidelines, an evidence-based minimum set of items for reporting in systematic reviews, were followed in this systematic review. Results:24 peer-reviewed papers were identified. They indicate that tapentadol toxicity can cause mortality and serious adverse effects. Conclusion(s): At least four confirmed fatalities, and serious adverse effects have been documented for individuals abusing or using tapentadol as prescribed. Serious adverse effects of tapentadol use may include respiratory depression, confusion, coma, hallucination/delusion, seizures, tachycardia, hypertension, agitation, tremor, miosis, hypotension, dyspnea, electrolyte abnormality, atrial fibrillation or severe upper abdominal pain. Tapentadol is unlikely to cause serotonin syndrome. The toxicity of tapentadol is significantly less than pure mu opioids, such as oxycodone.
引用
收藏
页码:327 / 339
页数:13
相关论文
共 56 条
[1]  
Afilalo Marc, 2010, J Pain Res, V3, P1
[2]   Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study [J].
Afilalo, Marc ;
Etropolski, Mila S. ;
Kuperwasser, Brigitte ;
Kelly, Kathy ;
Okamoto, Akiko ;
Van Hove, Ilse ;
Steup, Achim ;
Lange, Bernd ;
Rauschkolb, Christine ;
Haeussler, Juergen .
CLINICAL DRUG INVESTIGATION, 2010, 30 (08) :489-505
[3]  
[Anonymous], DRUG APPR PACK TAP H
[4]  
[Anonymous], 2016, IND J RHEUMATOL, DOI DOI 10.1016/J.INJR.2015.12.001
[5]   Comparative metabolism of tramadol and tapentadol: a toxicological perspective [J].
Barbosa, Joana ;
Faria, Juliana ;
Queiros, Odilia ;
Moreira, Roxana ;
Carvalho, Felix ;
Dinis-Oliveira, Ricardo Jorge .
DRUG METABOLISM REVIEWS, 2016, 48 (04) :577-592
[6]   Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data [J].
Baron, Ralf ;
Eberhart, Leopold ;
Kern, Kai-Uwe ;
Regner, Stefan ;
Rolke, Roman ;
Simanski, Christian ;
Toelle, Thomas .
PAIN PRACTICE, 2017, 17 (05) :678-700
[7]   Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study [J].
Baron, Ralf ;
Likar, Rudolf ;
Martin-Mola, Emilio ;
Blanco, Francisco J. ;
Kennes, Lieven ;
Mueller, Matthias ;
Falke, Dietmar ;
Steigerwald, Ilona .
PAIN PRACTICE, 2016, 16 (05) :580-599
[8]   Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study [J].
Baron, Ralf ;
Kern, Uwe ;
Mueller, Matthias ;
Dubois, Cecile ;
Falke, Dietmar ;
Steigerwald, Ilona .
PAIN PRACTICE, 2015, 15 (05) :471-486
[9]  
Biondi D, 2013, PAIN PHYSICIAN, V16, pE237
[10]   Tapentadol Toxicity in Children [J].
Borys, Douglas ;
Stanton, Matthew ;
Gummin, David ;
Drott, Tracy .
PEDIATRICS, 2015, 135 (02) :E392-E396